AN2 Therapeutics (ANTX) Total Non-Current Liabilities (2024 - 2026)
AN2 Therapeutics (ANTX) reported Total Non-Current Liabilities of $5.6 million for Q1 2026, down 36.22% quarter-over-quarter from $8.7 million in Q4 2025.
AN2 Therapeutics (ANTX) Total Non-Current Liabilities (2024 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 3 years of Total Non-Current Liabilities data on file, last reported at $5.6 million in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $5.6 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $5.6 million (changed N/A YoY), and the FY2025 annual result was $8.7 million, down 14.83% from the prior year.
- Total Non-Current Liabilities declined to $5.6 million in Q1 2026 per ANTX's latest filing, from $8.7 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $10.2 million in Q4 2024 and troughed at $5.6 million in Q1 2026.
- A 3-year average of $8.2 million and a median of $8.7 million in 2025 frame the typical range for Total Non-Current Liabilities.
- On a YoY basis, Total Non-Current Liabilities climbed as much as 14.83% in 2025 and fell as far as 14.83% in 2025.
- A 3-year view of Total Non-Current Liabilities shows it stood at $10.2 million in 2024, then declined by 14.83% to $8.7 million in 2025, then tumbled by 36.22% to $5.6 million in 2026.
- Business Quant data shows ANTX's Total Non-Current Liabilities at $5.6 million in Q1 2026, $8.7 million in Q4 2025, and $10.2 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 42,980.09 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 64.76 Mn |
| 10 | AN2 Therapeutics | 161.95 Mn | 161.95 Mn | - | 5.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.56 Mn |
| Dec 31, 2025 | 8.72 Mn |
| Dec 31, 2024 | 10.24 Mn |